Heart Failure Reversal Therapy Research Articles

LOW EJECTION FRACTION PATIENTS' RESPONSE TO HEART FAILURE REVERSAL THERAPY – A SINGLE CASE STUDY

In India, chronic heart failure (CHF) has increased significantly despite improved medicine therapy. The overall prognosis of CHF patients was found to be unsatisfactory due to a decreased ejection fraction or a low aerobic capacity in CHF patients, resulting in rising mortality and morbidity rates. Perhaps complementary and alternative medications can aid in the treatment of congestive heart failure as an adjuvant. Ayurveda is one approach which can be applied to the treatment. Several studies have demonstrated the efficacy of panchakarma therapy in treating a variety of illnesses, and it can be treated as Heart failure reversal therapy. Heart failure reversal therapy (HFRT) is a unique treatment intended to improve cardiorespiratory endurance in patients with CHF. This study quantifies the maximal aerobic capacity (MAC) of patients with CHF whose mortality and morbidity rates are rising. The objective of the present investigation was to assess the efficacy of HFRT as an adjuvant therapy for patients with CHF and a low ejection fraction. In the present case report, HF was treated for six months with conventional medicine. Then, only Ayurveda treatment was offered, along with lifestyle adjustment, after examining the cause and risk factors for heart disease. This case report thereby describes the beneficial role of Ayurveda in heart failure with poor ejection fraction (35%) in a 65-year-old male with comorbidities who has been treated in our institute for six months.

Impact of Ayurveda-based lifestyle modification, diet, and panchakarma on the hemodynamic parameters in heart failure patients with preserved ejection fraction

Abstract Background: Heart failure (HF) with preserved ejection fraction (HFpEF) is a medical problem with a growing prevalence that requires sophisticated management techniques. New management strategies for HF have constantly been called for by researchers, which has drawn our attention to Ayurveda, the traditional alternative medicine practiced extensively in India. One such treatment used to treat heart failure is Heart Failure Reversal Therapy (HFRT), which combines herbal therapies including Snehan, Swedan, Basti (per rectal drug administration), and Hridaydhara. Objective: The study is aimed to evaluate the effects of HFRT and Ayurveda Dinacharya on known chronic HFpEF patients. Materials and Methods: This observational study was conducted between May 2021 and October 2021, wherein patients (both genders) with HF (New York Heart Association, NYHA Class I, II, and III) having a left ventricular ejection fraction of more than 40 and aged between 18 and 60 years were identified. The effect of study therapy, HFRT, and Ayurveda Dinacharya over 7 days in 14 sittings was observed. A total of 73 patients with HFpEF underwent study therapy for 7 days. Data related to patient demographics on Cardiac Output (CO), Diastolic Blood Pressure (DBP), Heart Rate (HR), Left Ventricular (LV), Systolic Blood Pressure (SBP), Systemic Vascular Resistance (SVR), Systolic (SYS), End-diastolic volume (EDV), Ejection factor (EF), etc. were analyzed pre- and post-study. Results: There was a remarkable improvement in the mean values of SVR from day 1 to day 7. The mean value of SVR on day 1 was 2271.39 ± 509.66, and on day 7 was 1876.18 ± 315.21. Reduced SVR values mean the amount of LV force needed to open the aortic valve is also reduced. This causes more efficient pumping action in the left ventricle, reflected by increased CO and increased VO2 max, thus improving the quality of life. Conclusion: The HFRT therapy and Ayurveda Dinacharya for seven days demonstrated a significant change in the hemodynamics of HFpEF patients, thus improving the quality of life.

Evaluation of the Effect of Heart Failure Reversal Therapy on Anthropometric Obesity Parameters in Patients with Chronic Heart Failure: A Retrospective Analysis.

<p />

Evaluation of the Effect of Heart Failure Reversal Therapy on Exercise Capacity in Patients with Chronic Heart Failure and the Association with Co-morbidities

<p />

Evaluation of the Effect of Heart Failure Reversal Therapy (HFRT) on the Anthropometric Obesity Parameters in Patients of Chronic Heart Failure

Background: Chronic heart failure (CHF) is a common cause of mortality and morbidity. Obesity influences the CHF development and prognosis. This study was conducted to assess effect of Heart failure reversal therapy (HFRT), a combination of panchakarma and allied therapies, on anthropometric parameters in CHF patients. Methodology: This retrospective study was conducted on data of patients who visited Madhavbaug clinics in Maharashtra, India between July-December 2018. Selection was based upon the availability of complete baseline (day 1 of HFRT) and follow-up data (day 30 of HFRT) of CHF patients who were admitted for minimum 5 days for HFRT. Results: Out of 147 patients, 74.15% were males with mean age 59.15+10.28 years. There was statistically significant decrease (p&lt;0.05) in both mean BMI and abdominal girth at day 30 of HFRT. 42 of 147 patients (28.57%) had hypertension (HTN) with CHF, 22 patients (14.97%) had diabetes mellitus (DM) and 61 patients (41.49%) had both HTN and DM. In all these sub-groups, mean BMI and abdominal girth was significantly decreased (p&lt;0.05) at day 30. Strong positive correlation was found between BMI and abdominal girth on day 1 (R=0.9, P&lt;0.05) and day 30 (R=0.83, P&lt;0.05) by Pearson’s correlation. Similar correlation was found between the two parameters in subsets of CHF patients having HTN or DM or both DM and HTN (p&lt;0.05). Conclusion: HFRT decreased BMI and abdominal circumference significantly in CHF patients, irrespective of the presence of HTN or DM. Both the anthropometric parameters correlated strongly in all co-morbidity subsets of CHF patients.

Efficacy of heart failure reversal therapy program in post-menopausal females with reduced ejection fraction: An observational study

Background: Heart failure with reduced ejection fraction (HFrEF) has growing prevalence, especially in postmenopausal females. Heart failure reversal therapy (HFRT) is a combination of Panchakarma and allied therapies used by Ayurveda physicians for chronic heart failure patients. This observational study was done to evaluate HFRT in HFrEF-affected postmenopausal females. Materials and Methods: The study was conducted between January 2015 and December 2017 at a Madhavbaug Hospital in Khopoli, India. The data of HFrEF patients who were administered HFRT twice over 7 days in hospital were considered. VO2 max, distance covered on 6-min walk test (6MWT), weight, body mass index (BMI), abdominal girth, heart rate (HR), and blood pressure (BP) were compared to day 1 and 90 of HFRT. Results: Twenty females were enrolled with a mean age of 64.2 ± 4.38 years. There was a significant improvement in mean VO2 max (12.30 ± 2.12 vs. 13.45 ± 2.10, P 0.05). Conclusion: HFRT effectively increases the VO2 max, distance walked on 6MWT and decreases metabolic parameters in postmenopausal HFrEF patients.

To study the efficacy of heart failure reversal therapy (HFRT) program in elderly male patients with reduced EF

To study the efficacy of heart failure reversal therapy (HFRT) program in elderly male patients with reduced EF

Efficacy of heart failure reversal therapy (HFRT) in post-menopausal female patient with preserved ejection fraction (>40%)

Efficacy of heart failure reversal therapy (HFRT) in post-menopausal female patient with preserved ejection fraction (>40%)

Role of ayurveda-based heart failure reversal therapy program in chronic heart failure patients with preserved ejection fraction (> 40): an observational study

Role of ayurveda-based heart failure reversal therapy program in chronic heart failure patients with preserved ejection fraction (> 40): an observational study

Effect of Heart Failure Reversal Therapy Program on Chronic Heart Failure Patients: A Retrospective Study

Background: Chronic heart failure (CHF) is a major health issue despite of the available medications. Heart failure reversal therapy (HFRT), a combination of herbal treatment and allied therapies, has been advocated by Ayurveda physicians as an add-on therapy for CHF. Aim: The present study was conducted to evaluate the effect of HFRT on Maximum Aerobic Capacity (MAC), blood pressure (BP), body mass index (BMI) and dependency on conventional therapy in CHF Patients. Materials & Methods: The present retrospective study was conducted in July 2017, wherein the data of CHF patients (New York Heart Association, NYHA Class I–IV) who attended out-patient departments (OPDs) at Madhavbaug clinics in Maharashtra, India were identified. Data of patients who were administered HFRT (60-75 minutes) with minimum 7 sittings over 90 days (± 15 days) were considered. Variables were compared between day 1 and day 90 of HFRT. Observations and Results: Out of 79 patients included, 39 were males while 40 females. HFRT showed significant improvement in MAC by 50.35% (from 18.60(±7.01) to 27.97(±7.98), p

To Evaluate the Efficacy of Heart Failure Reversal Therapy Using NT-Probnp Levels in Patients with Chronic Heart Failure

Heart failure is considered as a life-threatening epidemic disorder affecting about 26 million world's population and associated with considerable morbidity, mortality and healthcare expenses. Despite the availability of a range of advanced treatments and sophisticated therapies the prevalence of heart failure represents a herculean challenge. To address the challenge, the current investigation was conducted by evaluating the efficacy of Heart Failure Reversal Therapy (HFRT) in reducing left ventricular distress by assessing N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in congestive heart failure (CHF) patients. Total 76 CHF patients with NYHA Class II and III were screened from March to May 2017 and 15 CHF patients with NT-proBNP = 300-1500 pg/ml were selected for the study. NT-proBNP is measured as a marker, the value of which increases with an increase in severity of CHF. The study therapy, HFRT comprises of traditional procedure of panchkarma that includes snehana (external oleation), swedana (passive heat therapy), hrudaydhara (concoction dripping treatment) and basti (medicated enema) was administered twice daily for 7 days. Post-HFRT, ARJ kadha was administered for next 12 weeks follow-up. NT-proBNP levels were measured after a follow-up period of 90 days along with some other parameters like BMI, VO 2peak (evaluated by cardiac stress test with modified Bruce protocol) and weight. The findings of the investigation revealed significant reduction in NT-proBNP levels (42.46%, p = 0.009), weight (4.82%, p = 0.0007) and BMI (3.67%, p = 0.034) at the end of the follow-up period. The study also yielded significant improvements in VO 2peak (50.96%, p = 0.004). The overall results suggest that HFRT can possibly be explored as add-on therapy or a feasible alternative for the effective management of CHF.

Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study

ObjectivesThe present study was designed to evaluate effect of heart failure reversal therapy (HFRT) using herbal procedure (panchakarma) and allied therapies, as add-on to standard CHF treatment (SCT) in chronic heart failure (CHF) patients. MethodsThis open-label, randomized study conducted in CHF patients (aged: 25–65 years, ejection fraction: 30–65%), had 3-phases: 1-week screening, 6-week treatment (randomized [1:1] to HFRT+SCT or SCT-alone) and follow-up (12-week). Twice weekly HFRT (60–75min) consisting of snehana (external oleation), swedana (passive heat therapy), hrudaydhara (concoction dripping treatment) and basti (enema) was administered. Primary endpoints included evaluation of change in metabolic equivalents of task (MET) and peak oxygen uptake (VO2peak) from baseline, at end of 6-week treatment and follow-up at week-18 (non-parametric rank ANCOVA analysis). Safety and quality of life (QoL) was assessed. ResultsSeventy CHF patients (n=35, each treatment-arm; mean [SD] age: 53.0 [8.6], 80% men) were enrolled in the study. All patients completed treatment phase. Add-on HFRT caused a significant increase in METs (least square mean difference [LSMD], 6-week: 1.536, p=0.0002; 18-week: −1.254, p=0.0089) and VO2peak (LSMD, 6-week: −5.52, p=0.0002; 18-week: −4.517, p=0.0089) as compared with SCT-alone. Results were suggestive of improved functional capacity in patients with HFRT (QoL; Mean [SD] HFRT+SCT vs. SCT-alone; 6-week: −0.44 [0.34] vs. −0.06 [0.25], p<0.0001 and 18-week: −0.53 [0.35] vs. −0.29 [0.26], p=0.0013). Seven treatment-emergent adverse events (mild severity) were reported in HFRT-arm. ConclusionFindings of this study highlight therapeutic efficacy of add-on HFRT vs. SCT-alone in CHF patients. The non-invasive HFRT showed no safety concerns.